Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
This Phase 3 trial showed tirzepatide, a GIP/GLP-1 dual receptor agonist, met the primary objective of non-inferiority versus dulaglutide, a GLP-1 receptor agonist, with an 8% lower rate of major adverse cardiovascular events (MACE) that included cardiovascular death, heart attack or stroke, while delivering greater reductions in A1C and weight
(2) included LT recipients
Whats the difference between these two
Step 1 Take your dose Take a free 2-minute quiz to share your health goals
The approved dose range for type 2 diabetes is 2.5 mg to 15 mg weekly, identical to the weight-loss range
US$ 23.12
US$ 26.35
US$ 29.60
